Literature DB >> 25374059

Association between endothelial nitric oxide synthase 894G>T polymorphism and prostate cancer risk: a meta-analysis of literature studies.

Cheng Zhao1, Weiqian Yan, Xiongbing Zu, Minfeng Chen, Longfei Liu, Shushan Zhao, Hong Liu, Xia Hu, Renna Luo, Yang Xia, Lin Qi.   

Abstract

To date, several studies have been conducted to assess the association between endothelial nitric oxide synthase (eNOS) gene 894G > T polymorphism and prostate cancer (PCa) risk, but the results are conflicting. To derive a more precise estimation of the relationship between 894G > T polymorphism and PCa risk, the present meta-analysis was performed. A total of eight case-control studies were included in this meta-analysis. The pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated to evaluate the associations. Our results suggested that 894G > T polymorphism is associated with PCa risk under codominant (GT vs. GG) (OR = 1.11, 95 % CI = 1.01-1.22, P = 0.04) and overdominant (GT vs. GG + TT) (OR = 1.12, 95 % CI = 1.02-1.23, P = 0.02) models in the overall population, while there are no associations observed under dominant (GT + TT vs. GG), recessive (TT vs. GG + GT), and allelic (T vs. G) models. Moreover, when the eligible studies were stratified according to sources of control, significant association between 894G > T polymorphism and susceptibility of PCa was also identified under codominant (OR = 1.12, 95 % CI = 1.01-1.24, P = 0.03) and overdominant (OR = 1.13, 95 % CI = 1.02-1.25, P = 0.02) models when using healthy individuals as control. However, there are no significant associations found under any genetic models when using BPH patients as control group. In conclusion, the present meta-analysis suggested that the eNOS gene 894G > T polymorphism might be a risk factor in the onset of PCa.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25374059     DOI: 10.1007/s13277-014-2097-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  39 in total

1.  The Glu298Asp polymorphism in the NOS3 gene and the risk of prostate cancer.

Authors:  Yonggang Zhang; Qingyi Jia; Qing He; Jiani Shen; Jiqiao Yang; Pei Xue; Mengmeng Ma; Rui Xu; Liang Du
Journal:  Tumour Biol       Date:  2014-02-28

2.  Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors.

Authors:  Xiangdong Le; Daoyan Wei; Suyun Huang; Jack R Lancaster; Keping Xie
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

3.  Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer.

Authors:  Meltem Ozlen Dillioglugil; Haluk Mekık; Bahar Muezzinoglu; T Alp Ozkan; Cennet Gural Demir; Ozdal Dillioglugil
Journal:  Int Urol Nephrol       Date:  2012-06-19       Impact factor: 2.370

4.  The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.

Authors:  Karina Marangoni; Adriana F Neves; Alexandra M Cardoso; Weruska Karyna Santos; Paula C Faria; Luiz R Goulart
Journal:  Cancer Detect Prev       Date:  2006-02-02

5.  Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium.

Authors:  Zhu Deqiu; Liu Kang; Yi Jiali; Liu Baolin; Liu Gaolin
Journal:  Biochimie       Date:  2010-11-21       Impact factor: 4.079

Review 6.  Prostate cancer epidemiology.

Authors:  Henrik Grönberg
Journal:  Lancet       Date:  2003-03-08       Impact factor: 79.321

Review 7.  Prostate cancer.

Authors:  Jan-Erik Damber; Gunnar Aus
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

8.  The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide.

Authors:  Bart A Veldman; Wilko Spiering; Peter A Doevendans; Gerald Vervoort; Abraham A Kroon; Peter W de Leeuw; Paul Smits
Journal:  J Hypertens       Date:  2002-10       Impact factor: 4.844

9.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

10.  Ephrin-A1 is up-regulated by hypoxia in cancer cells and promotes angiogenesis of HUVECs through a coordinated cross-talk with eNOS.

Authors:  Yong Song; Xiao-Ping Zhao; Kai Song; Zheng-Jun Shang
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more
  7 in total

1.  NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis.

Authors:  Wencheng Li; Min Gu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 2.  Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).

Authors:  Abbas Salihi; Mohammed A Al-Naqshabandi; Zhikal Omar Khudhur; Zjwan Housein; Harmand A Hama; Ramyar M Abdullah; Bashdar Mahmud Hussen; Twana Alkasalias
Journal:  Mol Med Rep       Date:  2022-05-26       Impact factor: 3.423

3.  Association of eNOS 27-bp VNTR, 894G>T and 786T>C polymorphisms with susceptibility to Legg-Calve-Perthes Disease in Iranian children.

Authors:  Mohammad Reza Azarpira; Mohammad Mahdi Ghilian; Mohammad Reza Sobhan; Masoud Mahdinezhad-Yazdi; Kazem Aghili; Hossein Ahrar; Hossein Neamatzadeh
Journal:  J Orthop       Date:  2019-02-26

Review 4.  The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention.

Authors:  Huzefa Vahora; Munawwar Ali Khan; Usama Alalami; Arif Hussain
Journal:  J Cancer Prev       Date:  2016-03-30

5.  eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.

Authors:  Andrea Casadei Gardini; Giorgia Marisi; Luca Faloppi; Emanuela Scarpi; Francesco Giuseppe Foschi; Massimo Iavarone; Gianfranco Lauletta; Jody Corbelli; Martina Valgiusti; Floriana Facchetti; Cristina Della Corte; Luca Maria Neri; Stefano Tamberi; Stefano Cascinu; Mario Scartozzi; Dino Amadori; Oriana Nanni; Elena Tenti; Paola Ulivi; Giovanni Luca Frassineti
Journal:  Oncotarget       Date:  2016-05-10

6.  Association Between 12 Polymorphisms of VEGF/Hypoxia/Angiogenesis Pathway Genes and Risk of Urogenital Carcinomas: A Meta-Analysis Based on Case-Control Studies.

Authors:  Jin-Bo Chen; Meng Zhang; Yu Cui; Pei-Hua Liu; Yan-Wei Qi; Chao Li; Xu Cheng; Wen-Biao Ren; Qia-Qia Li; Long-Fei Liu; Min-Feng Chen; He-Qun Chen; Xiong-Bing Zu
Journal:  Front Physiol       Date:  2018-06-11       Impact factor: 4.566

7.  Association of endothelial nitric oxide synthase (eNOS) polymorphisms with EGFR-mutated lung adenocarcinoma in Taiwan.

Authors:  Chun-Yao Huang; Ming-Ju Hsieh; Wen-Jun Wu; Whei-Ling Chiang; Tu-Chen Liu; Shun-Fa Yang; Thomas Chang-Yao Tsao
Journal:  J Cancer       Date:  2018-06-15       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.